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Simple Summary: Considering the pivotal role of Wnt/β-catenin signaling in AML development
and persistence, the current study addresses in AML, the prognostic value of Wnt/β-catenin signaling
molecules and the anti-leukemic value of Wnt/β-catenin inhibition. In silico analysis of RNAseq
data from AML patients and flow cytometric analysis of primary AML samples revealed that higher
levels of Wnt/β-catenin pathway is a poor prognostic marker. Next, we found that pharmacological
interference, through small molecule inhibitors of Wnt and/or GSK-3 signaling reduces AML cell
survival by sensitizing the leukemia cells to chemotherapeutic agents both in vitro and in vivo. Overall,
our findings suggested that Wnt-inhibitory therapy could overcome the prognostic significance of
patient risk stratification, standing as a therapeutic response for all subgroups of AML.
Abstract: Wnt/β-catenin signaling has been reported in Acute Myeloid leukemia, but little is
known about its significance as a prognostic biomarker and drug target. In this study, we first
evaluated the correlation between expression levels of Wnt molecules and clinical outcome. Then,
we studied—in vitro and in vivo—the anti-leukemic value of combinatorial treatment between Wnt
inhibitors and classic anti-leukemia drugs. Higher levels of β-catenin, Ser675-phospho-β-catenin
and GSK-3α (total and Ser 9) were found in AML cells from intermediate or poor risk patients;
nevertheless, patients presenting high activity of Wnt/β-catenin displayed shorter progression-free
survival (PFS) according to univariate analysis. In vitro, many pharmacological inhibitors of Wnt
signalling, i.e., LRP6 (Niclosamide), GSK-3 (LiCl, AR-A014418), and TCF/LEF (PNU-74654) but not
Porcupine (IWP-2), significantly reduced proliferation and improved the drug sensitivity of AML cells
cultured alone or in the presence of bone marrow stromal cells. In vivo, PNU-74654, Niclosamide and
LiCl administration significantly reduced the bone marrow leukemic burden acting synergistically
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with Ara-C, thus improving mouse survival. Overall, our study demonstrates the antileukemic role
of Wnt/β-catenin inhibition that may represent a potential new therapeutics strategy in AML.
Keywords: microenvironment; Wnt; AML; drug target
1. Introduction
Acute myeloid leukemia (AML) is the most common acute leukemia in adults; relapse after
chemotherapy still represents a critical problem in most patients, with only a 35–40% five-year
overall survival rate for non-promyelocytic AML [1,2]. Nevertheless, accurate biomarkers for early
diagnosis and response prediction to chemotherapy or allogeneic transplantation are still lacking [3].
The persistence of residual leukemia cells during chemo- or immunotherapy is favored by different
components of the bone marrow stromal niche through a redundant panel of molecular pathways, such
as Wnt, Notch and Hedgehog, supporting cell survival, proliferation and chemoresistance [4–6].
However, the role of these pathways in the interaction between AML cells and bone marrow
microenvironment is not entirely clear yet [7,8].
Wnt/β-catenin signaling is a developmental pathway mostly involved in tissue patterning during
embryonic development, through its ability to modulate proliferation, differentiation and motility of
embryonic and adult stem cells [9]. The pathway is activated when secreted Wnt proteins (Wnt-1,
Wnt-3a, Wnt-3b etc.) bind to the extracellular domain of the frizzled family of receptors and lipoprotein
receptor-related protein (LRP) co-receptors. This binding stabilizes β-catenin by disrupting the
β-catenin destruction complex consisting in GSK-3 and other proteins. The inactivation of the β-catenin
destruction complex promotes the nuclear accumulation of β-catenin, which in turn triggers the
expression of several target genes [10]. Deregulation of the pathway can occur in cancer, either as
result of gene mutations in components of Wnt/β-catenin pathway or because of the crosstalk between
tumor-associated stroma and cancer cell bulk. This deregulation can induce a persistent accumulation
of β-catenin in the nucleus, thus favoring cancer growth and dissemination, maintenance of cancer
stem cells, and drug resistance [11,12]. Considering the pivotal role of Wnt/β-catenin signaling in
several cancers, small molecules inhibitors have been developed as potent anticancer agents, including
inhibitors of Frizzled, Porcupine, GSK-3 and disruptors of the β-catenin/TCF/LEF complexes [13].
In AML, a number of studies support the contribution of the canonical Wnt signaling in the
maintenance of leukemia stem cells (LSCs) [14]. Indeed, many molecular events contribute to the
aberrant expression of the Wnt pathway in AML cells, such as FLT3 signaling, hypermethylation of the
secreted frizzled-related proteins, high levels of Frizzled receptors and Wnt ligands [15]. Moreover,
preclinical studies have demonstrated that activating the mutation of β-catenin in stromal cells is
sufficient to induce AML-like disease in mice [16]. Overall, the canonical Wnt signaling appears
relevant for leukemogenesis in AML and therefore drug targetable.
In this work, we demonstrate that pharmacological interference, through small molecules
inhibitors of Wnt and/or GSK-3 signaling reduces AML cell survival by sensitizing the leukemia cells
to chemotherapeutic agents both in vitro and in vivo. Consequently, combination treatments with
small molecules inhibitors of Wnt/GSK3 axis and chemotherapy may represent a novel therapeutic
strategy for a better chance of AML cell eradication.
2. Materials and Methods
2.1. Chemicals and Antibodies
The antibodies used for blast cell identification by Flow Cytometry (FACSCanto II, Becton
Dickinson, Rutherford, NJ, USA) were: anti-CD45-VioBlue, anti-CD45-APC-Vio770, anti-CD34-PerCP
and anti-CD117-APC all from Miltenyi Biotech (Bergsch gradbach, Germany). For Western
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blot analysis, anti-β-catenin, anti- Ser675-phospho-β-catenin, anti-Ser33/37/Thr41-phospho-β-catenin,
anti-non-phopho-β-catenin, anti-GSK-3β, anti-Ser9-phospho-GSK-3β, anti-GSK-3α, anti-Ser21-phospho-
GSK-3α anti-Histone H3 antibodies and Alexa 488-conjugated secondary antibodies were from Cell Signaling
(Danvers, MA, USA); anti-GAPDH, and HRP-conjugated secondary antibodies against mouse or rabbit
were from Sigma-Aldrich (Darmstadt, Germany). Wnt modulators used for proliferation and vitality assays,
i.e., Wnt-3a, PNU-74654, Niclosamide, IWP-2, Lithium Chloride (LiCl), and AR-A014418, were all purchased
from Sigma-Aldrich. For the analysis of cell death, Propidium iodide (PI) and FITC-conjugated Annexin V
were from Miltenyi Biotechnology. CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, Eden
Prairie, MN, USA) was from Promega (Promega, Milano, Italy). Cytarabine (Ara-C) and Idarubicin (Ida)
were provided by the Pharmacy Unit of the University Hospital of Verona.
2.2. Patients, Samples and Cell Lines
All cell samples were collected from AML patients and healthy donors after written informed
consent, as approved by the Ethics Committee of Azienda Ospedaliera Universitaria Integrata Verona
(N. Prog. 1828, 12 May 2010—‘Institution of cell and tissue collection for biomedical research in
Onco-Hematology’). In detail, AML blast cells were obtained from bone marrow or peripheral blood
samples of patients with AML at diagnosis (>80% of leukemia cells). Samples with less than 80% of
blast cells were enriched with CD34+ using MACS CD34 Microbead Kit (MiltenyiBiotec). AML patients
characteristics have been described elsewhere [17] and summarized in Table S1. Human bone marrow
mesenchymal stromal cells were obtained from bone marrow aspirates of healthy donors (hBM-MSCs,
n = 12) and AML patients (hBM-MSCs*, n = 18) after informed consent as previously described [17,18].
Human cell lines HL-60 (acute promyelocytic leukemia cell line), THP1 (acute monocytic leukemia cell
line), U937(myeloid histiocytic sarcoma cell line), were grown in complete RPMI-1640 medium (RPMI
supplemented with 10% FBS, 1% L-Glutamine solution 200 mM and 1% Penicillin/Streptomycin).
HEK-293 (human embryonic kidney cell line) and hBM-MSCs were maintained in complete DMEM.
Cell lines were purchased from the American Type Culture Collection. Flow cytometry of membrane
marker and cell morphology through Giemsa staining were used to check stability and identity of cell
lines as previously described [19]. Cell lines were routinely tested to be Mycoplasma-free.
2.3. Western Blotting
Immunoblotting were performed as previously described [19]. Briefly, Cells were lysed with the
RIPA lysis buffer (25 nM Tris pH 7.6, 150 mM NaCl, 1% NP40, 1% Na-deoxycholate, 0.1% SDS). Then,
samples were subjected to SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis)
followed by protein transfer onto nitrocellulose membrane (GE Healthcare, Chicago, IL, USA), that were
subsequently probed with antibodies specific to target proteins.
2.4. Cell Proliferation and Apoptosis and Viability Assays
The IC50 for each drug were obtained by analyzing treated cells with the colorimetric One
Solution Cell Proliferation Assay (MTS), as previously described [19,20]. Cell proliferation, cell
death and apoptosis were assessed through flow cytometric analysis of AML cells stained with
CFSE (carboxyfluorescein succinimidyl ester, proliferation) TOPRO-3 (cell death) and FITC-Annexin
V/Propidium Iodide (PI) (apoptosis) as previously described [17–19].
2.5. Xenograft Mouse Model
Animal care was performed in accordance with institution guidelines as approved by the Italian
ministry of health. Mice were purchased from Taconic (Germantown, NY, USA). Animal experiments
were carried in pathogen-free conditions at the animal facility of the Interdepartmental Centre of
Experimental Research Service of the University of Verona. Parameters used for sample size are power
of 80%, a signal/noise ratio of 2 and a significance level of 5% (p ≤ 0.05) using a one-sample t-test
power calculation. With a commitment to providing refinement, reduction and replacement (3Rs),
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application of factorial design to reduce the minimum group size was applied to obtain a minimum
group size of 5–8 mice. Xenograft mouse model were generated in NOD/Shi-scid/IL-2Rγnull (NOG,
Minnetonka, MN, USA) mice as previously described [17]. Briefly, U937 AML cell line (1 × 106) were
injected into the tail vein of totally irradiated (1.2 Gy, 137Cesium source), 8–12-week-old male mice.
At day 9 post-injection, mice (randomly allocated) received for 5 days intraperitoneal daily injection of
Ara-C (25 mg/Kg) or its vehicle (dimethyl sulfoxide, DMSO). In case of combined treatment, Ara-C or
DMSO were associated with each Wnt/GSK-3 inhibitor for the first two days, followed by three days of
Ara-C or DMSO. Mice were sacrificed after 2 weeks following the cell line injection, and bone marrow
leukemic burden was evaluated as percentage of human hCD45+ cells. No blinding was done. Wnt
inhibitors used for mouse experiments were PNU-74654 (0.5 mg/kg), Niclosamide (10 mg/Kg) and LiCl
(25 mg/Kg).
2.6. Cell Culture and Co-Culture
To study the capability of hBM-MSCs to support AML cell survival, AML cells were cultured in
suspension or on a confluent monolayer of hBM-MSCs with complete RPMI 1640 in 96-well plates:
105 AML blast cells or 2 × 104 cells from AML cell lines were cultured in 100 µL of complete RPMI
for 48 h. Wnt modulators, Ara-C and Idarubicin were added in co-culture. Co-cultured AML cells
were collected and stained with anti-CD45 antibodies conjugated to APC or PerCP and analyzed for
proliferation (CFSE dilution) and cell death (TOPRO-3, Annexin V/PI).
2.7. Flow Cytometry Analysis of Wnt Molecules
AML cell lines or AML blast cells identified as CD45+, CD34+, CD38- cells by flow cytometry,
were fixed and permeabilized for 30 min at 4 ◦C. Permeabilized cells were probed with primary
antibodies or their specific isotype for 1 h. Subsequently cells were washed and labelled for 30 min
with Alexa 488-conjugated secondary antibodies. Protein expression was then analyzed through flow
cytometry and expressed as relative median of fluorescence intensity (rMFI), defined as the ratio of the
specific antibody fluorescence over the specific isotype fluorescence.
2.8. Gene Reporter
To monitor Wnt/β-catenin transcriptional activity, we transfected THP1 with reporter plasmids
encoding for an inducible TCF responsive GFP reporter (Qiagen, Hilden, Germany) as previously
described [8] GFP signal was observed through Axiovert Z1 (Zeiss, Sheung Kehen, Germany) and
quantitatively measured by flow cytometry. The Wnt pathway activity was determined by normalizing
the activity of TCF-GFP to that of CMV-GFP plasmid.
2.9. RNA-seq Analysis
RNA-seq data from 173 AML patients were obtained as part of The Cancer Genome Atlas project
(TCGA). Gene expression data in Z-score format were downloaded from the cbioportal R package
cgdsr for the TCGA-LAML. Normalized data were used for Z-score calculation. For each mRNA,
a sample showing a Z-score higher or lower than the average Z-score for the whole population was
considered as expressing highly or lowly, respectively, the corresponding gene, Z > +/− 1.96; p < 0.05.
This strategy was applied for the gene of the WNT signaling pathways (APC, AXIN1, CTNNB1, FZD4,
GSK3A, GSK3B, LRP5, TCF4, WNT3A, WNT5A, WNT5B, WNT10A, WNT10B).
2.10. Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (La Jolla, CA, USA).
Mann–Whitney and Kruskal–Wallis were used to compare two groups or more than two groups,
respectively. All tests were one-sided. Pearson Chi-square analysis was used to test association among
variables. Survival curves were calculated by the Kaplan–Meier Method.
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3. Results
3.1. Wnt/GSK-3 Axis Is Functional in AML Cell Lines
We first evaluated in three AML cell lines, HL-60, THP1 and U937, the basal expression and
activation of the Wnt molecules, including total β-catenin, pan-phosphorylated β-catenin(Ser33–37/Thr41),
Ser675-phospho-β-catenin, active non-phospho-β-catenin, GSK-3β (total and Ser9) and GSK-3α (total
and Ser9). These proteins were expressed in all the three cell lines (Table 1). Western immunoblot of
nuclear fraction confirmed the activation of the Wnt/β-catenin pathway, since β-catenin was found in the
nuclear fraction of lysate for each cell line (Figure S1A). Next, we used a pharmacological approach to
confirm the activation of the pathway in AML cell lines by adding Wnt inhibitors (PNU-74654, IWP-2 and
Niclosamide) or GSK-3 inhibitors (LICL, AR-A014418) in the culture medium. Cells were treated with
increasing concentrations of each inhibitor, then cell viability was assessed through MTS. The samples
treated with all the GSK-3 and Wnt inhibitors, except IWP-2, displayed reduction in cell viability in a
dose-dependent manner (Figure S1B). As MTS assay cannot discriminate cell death or cell proliferation,
cell lines were treated with a single concentration (close to the IC50) of each drug, and then cell death and
proliferation were analyzed using TOPRO-3 and CFSE staining. Except Niclosamide, which induced a
strong effect, the other Wnt inhibitors PNU-74654 and IWP-2 slightly reduced cell viability, while inducing a
significant reduction in cell proliferation (Figure 1A,B). GSK-3 inhibitors, including LiCl and AR-A014418,
induced a significant reduction in both cell viability and proliferation (Figure 1A,B) in all the tested cell lines.
THP1 cell line, expressing higher levels of Wnt proteins compared to the two other cell lines (Table 1 and
Figure S1A,B), was mostly sensitive to Wnt inhibitors (Figure 1A). The use of Wnt ligands, such as Wnt-3a
and Wnt-5a, did not modify either cell proliferation or cell survival (Figure S1C).
Table 1. Flow cytometric analysis of Wnt/β-catenin and GSK-3 molecules in AML cell lines. HL-60,
THP1 and U937 were probed with specific primary antibodies and labelled with Alexa 488-conjugated
secondary antibodies. Data are expressed as relative median of fluorescence intensity and reported as
mean ± SEM of 6 independent experiments.
Relative Expression of Wnt Molecules in
AML Cell Lines HL-60 THP1 U937
Relative median of fluorescence intensity (rMFI) ± SEM
Total β-catenin 2.466 ± 0.238 6.765 ± 1.508 2.781 ± 0.288
Non-phospho-β-catenin 1.676 ± 0.058 2.360 ± 0.209 1.442 ± 0.0677
Ser675-phospho-β-catenin 3.471 ± 0.202 7.847 ± 1.443 3.398 ± 0.566
Ser33/37/Thr41-phospho-β-catenin 2.135 ± 0.119 3.013 ± 0.395 2.232 ± 0.21
GSK-3α 2.275 ± 0.161 2.654 ± 0.298 2.194 ± 0.18
pGSK-3α (Ser21) 9.355 ± 1.641 1.640 ± 2.678 7.901 ± 1.643
GSK-3β 2.217 ± 0.139 2.456 ± 0.293 1.713 ± 0.064
GSK-3β (Ser 9) 4.600 ± 0.416 9.401 ± 3.046 3.935 ± 0.643
3.2. Wnt Molecules Are Enriched in Patient Samples
To determine whether the Wnt/β-catenin pathway was represented in patient samples, we first
used in silico analysis of RNA-seq data from more than 170 AML patients that were part of The Cancer
Genome Atlas (TCGA) project on AML [21]. We observed that several genes of the Wnt/GSK-3/β-catenin
axis were enriched in AML samples, including AXIN, APC, CTNNB1 (BETA-CATENIN), GSK-3A and
GSK-3B (Figure 2). We then used flow cytometric analysis to determine the Wnt expression pattern in a
cohort of 60 AML patients admitted to our institution. Consistently with in silico analysis, we observed
in primary AML samples, a robust expression of β-catenin (total and phosphorylated forms), GSK-3β
(total and Ser9) and GSK-3α (total and Ser21) (Figure 3A). However, the expression levels of each
protein were not homogeneous amongst samples. To investigate whether this heterogeneous expression
of Wnt molecules could have prognostic significance, the samples were classified according to the
expression degree (high versus low) as compared to the mean values of expression for all samples.
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Then, we used a Kaplan–Meier analysis to determine patient survival in the two groups, censoring
data after 36 months. For all the proteins considered, no significant differences were observed neither
in overall survival (OS), nor in progression free survival (PFS). By contrast, when we considered the
activation of β-catenin pathway as the ratio between the non-active form (Ser33/37/Thr41 β-catenin)
and the total β-catenin, patients with low activation status (high ratio) displayed a better PFS
compared to patients presenting high activation status of the pathway (low ratio) (Figure 3B). Pearson
analysis showed a positive association between leucocyte count (WBC) and expression levels of
pan-phospho-β-catenin (Ser33–37/Thr41), Ser 675-phospho-β-catenin, non-phospho-β-catenin and
GSK-3β (Table 2A). A positive association was also found between hemoglobin (Hb) level and
active β-catenin (non-phosphorylated), phospho-GSK-3β (Ser 9), pan-phospho-β-catenin and Ser
675-phospho-β-catenin) (Table 2B). The European Leukemia Network (ELN) recommendations for
diagnosis and management of AML in adults has proposed the stratification of AML patients according
to genetic and molecular characteristics, dividing patients into three risk categories that are relevant
for clinical outcomes, i.e., good/favorable, intermediate, poor/adverse [22]. Accordingly, thanks to the
cytogenetics and mutational pattern of each patient, we classified patients in these three risk groups,
observing that β-catenin, Ser675-phospho-β-catenin and GSK-3α (total and Ser21) were preferentially
expressed in adverse and intermediate risk groups (Figure 4). All these observations suggested that
Wnt or GSK signaling could be associated with AML chemosensitivity.Cancers 2020, 12, x  15 of 15 
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Table 2. Correlation between hemogram and Wnt signaling expression in AML blast cells. Spearman
analysis was used to assess the correlation between Wnt protein levels in blast cells and parameters of
the hemogram, including (A) white blood cells (WBC); (B) Hemoglobin (Hb), and (C) platelets (PLTS).
Statistical significance when p ≤ 0.05.
(A) White Blood Cells (WBC)
WBC GSK3α GSK3β Non-Phospho-
β-catenin
Total
β-Catenin
Phospho-GSK-
3α (Ser 21)
Phospho-GSK3β
(Ser 9)
Ser33/37/Thr41-
Phospho-β-Catenin
Ser675-Phospho-
β-Catenin
r 0.1117 0.3236 0.3205 0.2317 0.1109 0.2414 0.4311 0.4106
p value 0.2583 0.0271 0.0284 0.0870 0.2597 0.0780 0.0043 0.0064
(B) Hemoglobin (Hb)
Hb GSK3α GSK3β Non-Phospho-
β-Catenin
Total
β-Catenin
Phospho-GSK-
3α (Ser 21)
Phospho-GSK3β
(Ser 9)
Ser33/37/Thr41-
Phospho-β-Catenin
Ser675-Phospho-
β-Catenin
r −0.02664 −0.02471 0.09962 0.002832 0.1640 0.2041 0.1749 0.2092
p value 0.4387 0.4431 0.2816 0.4935 0.1696 0.1162 0.1538 0.1104
(C) Platelets (PLTS)
PLTS GSK3α GSK3β Non-Phospho-
β-Catenin
Total
β-Catenin
Phospho-GSK-
3α (Ser 21)
Phospho-GSK3β
(Ser 9)
Ser33/37/Thr41-
Phospho-β-Catenin
Ser675-Phospho-
β-Catenin
r 0.2725 0.2478 0.4430 0.1463 0.2366 0.3473 0.3730 0.4452
p value 0.0539 0.0726 0.0034 0.1972 0.0824 0.0190 0.0125 0.0033
3.3. hBM-MSCs Express Wnt Molecules but are Insensitive to Pathway Inhibitors
Considering the importance of bone marrow microenvironment in AML onset and recurrence,
ex-vivo co-culture of leukemic cells on bone marrow stromal monolayer represents a good tool for
evaluating drug sensitivity [23,24]. Bone marrow stromal cells from healthy donors and patients
were analyzed for expression of components of Wnt/GSK-3/β-catenin axis. Western blot analysis
highlighted that all healthy donors hBM-MSCs (n = 12) and AML-hBM-MSCs (hBM-MSCs*, n = 18)
samples expressed Wnt components, suggesting a possible paracrine signal between hBM-MSCs and
leukemic cells. The presence of active forms of β-catenin, including non-phospho-β-catenin and
Ser675-phospho-β-catenin [25], revealed a constitutive activation of the Wnt/β-catenin pathway in
these cells (Figure 5A). To assess whether hBM-MSC and AML cell co-culture induces the activation
of Wnt/β-catenin in AML cells, we used THP1 cells expressing the TCF/LEF-GFP reporter gene.
Transfected cells seeded on hBM-MSCs displayed enhanced GFP signal (Figure 5B) and the increase in
TCF/LEF activity was similar to that observed when cells were challenged with Wnt-3a (Figure 5B).
As the inhibition of the pathways could theoretically interfere with some hBM-MSC functions,
we assessed hBM-MSC viability through MTS assay with increasing concentrations of Wnt/GSK-3
inhibitors. hBM-MSCs and hBM-MSCs* viability was not altered by Wnt/GSK-3 inhibitors unless at
very high concentrations (Figure 5C). We also analyzed immunomodulatory properties and adipogenic
or osteogenic differentiation of hBM-MSCs treated with Wnt or GSK-3 inhibitors for 48 h; hBM-MSCs
retained the same capability both to suppress stimulated PBMC proliferation (Figure S2A) and to
undergo differentiation into osteocyte and adipocytes (Figure S2B).
3.4. Wnt Modulators Enhance Chemosensitivity of AML Cells
We assessed whether Wnt inhibitors could increase AML cell sensitivity to drugs normally used
for AML therapy, such as Idarubicin or Ara-C. AML cells were cultured alone or in the presence
of hBM-MSCs for 48 h, with or without Wnt modulators and chemotherapeutic agents. Cells were
harvested, stained with annexin and analyzed for apoptosis. Idarubicin (0.5 µM) or Ara-C (10 µM)
significantly induced the apoptosis of both AML cell lines and AML primary cells, while co-culture
with hBM-MSCs led to a significant rescue effect (Figure 6A and Figure S4). The addition of PNU-74654
(15 µM), Niclosamide (1.5 µM), LiCL (15 mM) or AR-A014418 (15 µM) significantly lowered the
anti-apoptotic effect on AML cells mediated by bone marrow stromal cells, regardless their origin
(hBM-MSCs or hBM-MSCs*) and the ELN risk classification of the AML patients.
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S5) of HL-60 and THP1 cell lines treated for 48 h with Wnt or GSK-3 inhibitors, including PNU 74,654
(15 µM), IWP-2 (15 µM), Niclosamide (1 µM), LiCl (15 mM) and AR-A014418 (15 µM). Images are
representative of at least 3 experiments.
To investigate which microenvironmental prosurvival protein network was affected by Wnt
pharmacological inhibition, we first analyzed how the Wnt-GSK axis was modulated in AML cell
lines treated with above mentioned inhibitors, observing that the pattern of modulation was cell
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line-dependent, probably reflecting differential modulation of the pathway according to molecular
features of the AML cell/samples (Figure S6). Briefly, Niclosamide and PNU-74654 reduced the levels of
Ser675-phospho-β-catenin in the HL-60 cell line, whereas Niclosamide induced reduced levels of both
total β-catenin and the pan-phospho-β-catenin in the THP1 cell line. Of note, as previously described,
the PNU-74654 treatment induced increased levels of total β-catenin [26]. This effect could be related to
the accumulation of the protein in the cytoplasm, because the inhibition of the Tcf/β-catenin complex,
PNU-74654, decreased nuclear β-catenin accumulation (Figure S6A) [26]. In contrast, both Wnt and
GSK-3 inhibitors were associated with reduced phosphorylation of GSK-3β at Ser 9 (Figure S6B). Then,
we analyzed the expression and activation of Bcl-2, mT/Akt and MAP kinase family proteins in THP1
and HL-60 cell lines treated with above mentioned inhibitors. A persistent modulation of Bax, STAT-3,
Akt, NF-κB, and ErK 1/2 was clearly evident (Figure 6B).
To assess whether he anticancer effect of Wnt and GSK-3 inhibitors could be operational in vivo,
we generated a xenograft model of AML by injecting the U937 cell line in the tail vein of NOG mice,
as previously described [17]. Two weeks later, the mice were treated with either Ara-C alone or Ara-C
in combination with each inhibitor (except AR-A014418 for its known toxicity). Treatment of engrafted
mouse with Ara-C significantly reduced the leukemic burden in mouse bone marrow (Figure 7A),
but this effect was stronger when Ara-C was associated with either PNU-74654, Niclosamide, or LiCl.
Accordingly, the mean of mouse survival was significantly improved when Ara-C was associated with
each inhibitor, i.e., PNU-74654 (33 days), Niclosamide (29 days) and LiCl (33 days), as compared to
mice treated with Ara-C alone (mean survival = 26 days) (Figure 7B).
Cancers 2020, 12, x  15 of 15 
 
Niclosamide, or LiCl. Accordingly, the mean of mouse survival was significantly improved when 
Ara-C was associated with each inhibitor, i.e., PNU-74654 (33 days), Niclosamide (29 days) and LiCl 
(33 days), as compared to mice treated with Ara-C alone (mean survival = 26 days) (Figure 7B). 
 
Figure 7. Wnt inhibition reduces bone marrow leukemic burden and prolongs survival of the cell line-
based AML xenograftmouse model. (A,B) Flow cytometry analysis of human CD45+ in bone marrow 
samples obtained from mice transplanted with AML cell line U937. Starting from day 9 post-
engraftment, mice were treated for 2 days with one of the following schedules: DMSO, Ara-C alone 
(25 mg/Kg), Wnt inhibitor alone, or Wnt inhibitor + Ara-C. Then Ara-C were administered for further 
3 days in the groups receiving Ara-C (alone or in combination), while the other groups received 
DMSO. The following concentrations were used for each inhibitor: PNU-74654 0.5 mg/kg, 
Niclosamide 10 mg/Kg, LiCl 25 mg/Kg. The assay was performed with at least 5 mice in each group. 
Data are reported as mean ± SEM of values obtained from at least 5 mice. (C) Survival of mice 
transplanted with U937, differences in survival curves were analyzed with the Log-rank (Mantel–
Cox) Test, * p < 0.05, *** p < 0.001. 
4. Discussion 
Targeted treatments using small molecule inhibitors are extensively studied as promising 
strategies to eradicate drug resistance in cancer and in AML [27]. In this study, we demonstrated—
in vitro, ex vivo and in vivo in a murine model—that the use of pharmacological inhibitors of Wnt/β-
catenin enhances the effectiveness of chemotherapeutic agents in eradicating AML cells. 
The rationale for using pharmacological inhibitors of Wnt signaling as anti-leukemic agents is 
the evidence of aberrant activation of Wnt pathway in AML samples [28,29]. Through flow cytometric 
analysis, we confirmed that β-catenin was present in AML primary cell samples in a variable 
phosphorylated status, including the Ser675-phospho-β-catenin and the (Ser33/37/Thr41)-phospho-
β-catenin. Considering the heterogeneity of each AML sample, we did not use Western blot of nuclear 
fraction as a method to analyze Wnt activation in samples. We took the (Ser33/37/Thr41)-phospo-β-
catenin/total β-catenin ratio as a surrogate for assessing Wnt/β-catenin activation, demonstrating that 
the pathway is constitutively active in a large portion of patients. Besides the robust expression of β-
catenin, we also observed a robust expression of different forms of GSK-3 proteins in AML samples. 
Within the Wnt/β-catenin cascade, GSK-3 is considered as a negative regulator of the pathway [30,31]. 
Its inhibition is often used as an indirect strategy to stabilize cellular β-catenin [32,33]. Nevertheless, 
we report here that the use of GSK-3 inhibitors reduced cell viability, similarly to Wnt inhibition. 
There are at least two pools of GSK-3, one associated with Axin and involved in β-catenin 
phosphorylation, the other not associated with Axin. Interestingly, Wnt signaling can modulate both 
. Wnt inhib tion reduces bone marrow leukemic burde and prolongs survival of the cell
line-based AML xenograftmouse model. (A,B) Fl w cytometry analysis of human CD45+ in b ne
marrow sampl s obtained from mice transplanted with AML cell line U937. Starting from day 9
post-engraf ment, mic w re treated for 2 days with one of the following schedules: DMSO, Ara-C
alone (25 mg/Kg), Wnt inhibitor alone, or Wnt inhibitor + Ara-C. Then Ara-C were administered fo
further 3 days in the groups receiving Ara-C (al ne or in combination), while the other groups r i
The foll wing con e trations were used for each inhibitor: PNU-74654 0.5 mg/kg, Niclosamide
10 mg/kg, LiCl 25 mg/kg. The assay was performed with at least 5 mice in each group. Data are
reported as mean ± SEM of values obtained from a least 5 mice. (C) Survival of mice transpl nted with
U937, diff rences in survival curv were analyzed with the Log-rank (Mantel–Cox) Test, * p < 0.05,
*** p < 0.001.
Cancers 2020, 12, 2696 12 of 16
4. Discussion
Targeted treatments using small molecule inhibitors are extensively studied as promising strategies
to eradicate drug resistance in cancer and in AML [27]. In this study, we demonstrated—in vitro,
ex vivo and in vivo in a murine model—that the use of pharmacological inhibitors of Wnt/β-catenin
enhances the effectiveness of chemotherapeutic agents in eradicating AML cells.
The rationale for using pharmacological inhibitors of Wnt signaling as anti-leukemic agents is the
evidence of aberrant activation of Wnt pathway in AML samples [28,29]. Through flow cytometric analysis,
we confirmed that β-catenin was present in AML primary cell samples in a variable phosphorylated
status, including the Ser675-phospho-β-catenin and the (Ser33/37/Thr41)-phospho-β-catenin. Considering
the heterogeneity of each AML sample, we did not use Western blot of nuclear fraction as a method to
analyze Wnt activation in samples. We took the (Ser33/37/Thr41)-phospo-β-catenin/total β-catenin ratio
as a surrogate for assessing Wnt/β-catenin activation, demonstrating that the pathway is constitutively
active in a large portion of patients. Besides the robust expression of β-catenin, we also observed a robust
expression of different forms of GSK-3 proteins in AML samples. Within the Wnt/β-catenin cascade, GSK-3
is considered as a negative regulator of the pathway [30,31]. Its inhibition is often used as an indirect strategy
to stabilize cellular β-catenin [32,33]. Nevertheless, we report here that the use of GSK-3 inhibitors reduced
cell viability, similarly to Wnt inhibition. There are at least two pools of GSK-3, one associated with Axin
and involved in β-catenin phosphorylation, the other not associated with Axin. Interestingly, Wnt signaling
can modulate both β-catenin-associated GSK-3 and β-catenin-independent GSK-3 [30,34]. Evidence from
the literature also shows that GSK-3 is not only involved in the Wnt signaling, but also crosstalk with
multiple others survival pathways, such as Notch, Hegehog and Akt-related cascades [27,32,34–38]. As the
role of GSK-3 cannot be only related to Wnt/β-catenin signaling, we cannot exclude the involvement of a
GSK-3-independent Wnt signaling in AML pathogenesis [27,32,34–38]. Interestingly, a previous work has
demonstrated that GSK-3 inhibition can improve 1,25-dihydroxyvitamin D3-mediated differentiation of
AML cells, suggesting that a combinatorial treatment including GSK-3 inhibitors and anti-leukemic drugs is
a promising and safety strategy in AML [39].
Wnt/β-catenin signaling is a multiple step cascade. The importance of each step for cancer
development is disease- and cell context-dependent [40,41]. The inhibitors used in this study were
chosen for their ability to interfere with specific steps of the pathway, i.e., ligand and receptors
(IWP-2 and Niclosamide), GSK-3 (LiCl, AR-A014418), or nuclear transactivation or TCF/LEF complex
(PNU-74654 and PKF118-310). While all GSK-3 inhibitors and TCF/LEF inhibitors showed the same
activity for each member of Wnt family, IWP-2 failed to reproduce the capability of Niclosamide of
reducing AML cell viability and sensitizing them to drugs. This discrepancy can be explained by the
mechanisms triggered by each of the inhibitors; in fact, IWP-2 interferes with biogenesis of Wnt ligand,
by targeting porcupine, while Niclosamide interferes directly with the co-receptor LRP-6 [13,42].
Our data show that small molecule inhibitors of Wnt or GSK-3 substantially enhance the antitumor
effect of Ara-c and Idarubicin in vitro and reduce AML cell survival advantage, thus lowering the
leukemic burden in the bone marrow of AML mouse models. The mechanisms involved in Ara-C
or Idarubicin-induced cell death include the modulation of many pathways, such as mTor/Akt, Erk,
NF-KB, stat3, Bax/Bak etc [17,18,43–45]. Through Western blot analysis, we clearly showed that
these proteins were down-regulated in AML cell lines treated with Wnt or GSK-3 inhibitors. These
observations are in favor of a synergistic activity between our inhibitors and the chemotherapeutic
agents used in this study. We cannot exclude the interaction with other specific mechanisms of drug
resistance, but Wnt/β-catenin signaling seems to play a pivotal role in this phenomenon.
The main molecular events related to Wnt pathway activation in AML are both chromosomal
translocations and/or mutations of FLT3 [15]. Enhanced FLT3 signaling is similarly associated to
poor prognosis in AML [22]. However, aberrant Wnt signaling was also observed in patients with
normal karyotype, i.e., patients classified as an intermediate-risk group according to WHO and ELN
classifications [15,46]. We observed a significant expression of total β-catenin, Ser675-phospo-β-catenin,
and GSK-3α (total and Ser 21) molecules in intermediate- and adverse-risk patients compared to
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favorable-risk groups. In addition, we found a significant association between Wnt/β-catenin activation
and PFS, suggesting that Wnt/β-catenin signaling could be related to the persistence of residual leukemic
cells along the treatment course. Residual resistant cells are mainly found in the bone marrow, as the
result of a close interaction between bone marrow microenvironment and AML blast cells and leukemia
stem cells. This phenomenon is associated with drug resistance and relapse [47–49]. Several literature
data permit to elaborate a model of AML development, according to which Wnt/β-catenin is both
involved in the crosstalk between stromal cells and AML cells, and in autocrine signaling amongst AML
cells [46,50]. Our co-culture data support this hypothesis, demonstrating through gene reporter assays
the presence of enhanced activity of Wnt/β-catenin in AML cells cultured on stromal cell monolayers.
In the model of AML leukemogenesis induced by activating mutation in β-catenin, the stromal cell
contribution is at least equal to the role played by hematopoietic cells [16]. Thus, Wnt inhibition may
sensitize AML cells to therapy by both targeting directly resistant cells and interfering with the stromal
cell support towards leukemic cells that is necessary for the persistence and selection of resistant
clones [48]. Therefore, Wnt-inhibitory therapy could overcome the prognostic significance of patient
risk stratification, standing as a therapeutic response for all subgroups of AML.
5. Conclusions
Overall, our study demonstrates that because of their capabilities to interfere with AML cell
growth and chemoresistance, small molecule inhibitors of Wnt and GSK-3 signaling may represent
potential candidates for drug development in AML.
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